Neuroendocrine Tumor Lung - Key Symptoms and Treatment

Neuroendocrine Tumor Lung Overview: Causes, Sypmtoms & Treatment

You've been coughing for months. The chest X-ray showed something unusual. Now your doctor mentions neuroendocrine tumour lung (NET).

What is Neuroendocrine Tumour Lung?

It's a tumour arising from neuroendocrine cells within lung tissue. These specialised cells produce hormones and neurotransmitters throughout the body. When genetic mutations accumulate, these cells may transform into cancerous tumours.

Standard adenocarcinomas and squamous cell carcinomas develop from epithelial cells lining airways. By contrast, NETs originate from neuroendocrine cells scattered throughout lung tissue that normally regulate various physiological processes.

Types of Neuroendocrine Tumour Lung

Different types fall along a spectrum from slow-growing to highly aggressive. Understanding distinctions helps predict behaviour and guide treatment choices.

Typical carcinoid tumours

Typical carcinoids represent the lowest-grade neuroendocrine carcinoid tumour lung category. These tumours grow extremely slowly, often over many years before causing symptoms. They rarely spread beyond the lung.

Cell division occurs infrequently under microscopic examination. Tissue death (necrosis) remains characteristically absent, distinguishing them from higher-grade tumours.

Symptoms develop gradually over months or years. Some discoveries occur incidentally during chest imaging for unrelated conditions.

Atypical Carcinoid Tumours

Atypical carcinoids occupy the middle ground between typical carcinoids and high-grade NETs. They grow moderately faster than typical carcinoids and carry a higher risk of spreading to lymph nodes and distant organs.

Pathologists identify these through increased mitotic activity visible under microscopy. Cell division rates typically range from two to ten mitoses per ten high-power fields.

Small areas of tissue death may appear scattered throughout the tumour, another distinguishing feature from typical carcinoids.

Five-year survival rates range from 60-80% depending primarily on stage at initial diagnosis.

Large Cell Neuroendocrine Carcinoma (LCNEC)

Large cell neuroendocrine carcinoma (LCNEC) represents aggressive, high-grade disease. These tumours grow rapidly, often doubling in size within weeks rather than months. They spread early to lymph nodes and distant organs, frequently before causing obvious symptoms.

LCNEC frequently metastasises before diagnosis, with many patients presenting with advanced-stage disease at initial evaluation. Lymph node involvement occurs commonly throughout the chest.

Overall prognosis remains challenging despite aggressive multimodality treatment.

Small Cell Lung Cancer (Neuroendocrine Type)

Small cell lung cancer represents the most aggressive NET category recognised in thoracic oncology.

These tumours grow extremely rapidly, with doubling times measured in mere weeks. They spread throughout the body early in the disease course, often metastasising before the primary tumour becomes large enough to cause local symptoms.

By the time of diagnosis, most patients already have metastatic disease affecting multiple organ systems.

Lung Neuroendocrine Tumour Classification

The classification organises these tumours into low-grade, intermediate-grade, and high-grade categories. This system predicts behaviour and guides treatment choices.

• •Low-grade NETs
  Include typical carcinoid tumours. These grow slowly over the years. Surgical removal often achieves a cure.
• •Intermediate-grade NETs
  Comprise atypical carcinoid tumours. Growth occurs moderately. Surgery remains the primary treatment.
• •High-grade NETs
  Encompass LCNEC and small cell lung cancer. Rapid growth characterises these tumours. Chemotherapy forms the treatment backbone.

Classification directly impacts treatment decisions. Low-grade disease focuses on surgery. High-grade disease requires immediate systemic chemotherapy.

Neuroendocrine Tumour Lung Symptoms

Neuroendocrine tumour lung symptoms vary based on tumour location, size, and hormone production. Many patients initially experience vague respiratory complaints that persist despite treatment attempts.

Common respiratory symptoms include:

• •Persistent cough:
  Lasts weeks or months without improvement despite medications
• •Chest pain:
  Ranges from mild discomfort to severe pain, worsening with deep breathing
• •Shortness of breath:
  Worsens gradually over time, limiting physical activities
• •Wheezing:
  Suggests airway obstruction by a growing tumour mass
• •Recurrent infections:
  Tumours blocking airways trap secretions, fostering bacterial growth
• •Coughing blood:
  Indicates direct airway invasion by tumour tissue

Smokers often attribute them to chronic bronchitis initially. Non-smokers may dismiss symptoms as prolonged respiratory infections. This diagnostic delay sometimes allows tumours to progress before detection.

Unexplained weight loss suggests advanced disease. Cancer fatigue develops as tumours grow larger and metabolic demands increase. Loss of appetite accompanies progressive disease frequently, contributing to further weight loss.

Hormone-Related Symptoms in Lung NETs

Hormones produced by functional NETs cause distinctive symptoms in approximately 10% of cases. Carcinoid syndrome represents the most recognised pattern.

Facial flushing happens episodically. Redness spreads across face and neck suddenly. Episodes last minutes to hours.

Causes of Neuroendocrine Tumour Lung

The causes of the condition remain incompletely understood. Several factors increase risk.

• •Genetic mutations
  drive NET development. Specific gene changes affect neuroendocrine cell growth regulation. MEN1 gene mutations predispose to various neuroendocrine tumours, including lung NETs.
• •Smoking
  increases all lung cancer risks, including NETs. High-grade NETs are particularly associated with heavy tobacco exposure. The cancer risk factors for high-grade NETs mirror those for common lung cancers.
• •Environmental exposures
  like radon and asbestos potentially raise NET risk, though specific triggers remain poorly defined.

Neuroendocrine Tumour Lung Diagnosis

Neuroendocrine tumour lung diagnosis requires multiple tests combining imaging and tissue sampling.

Imaging tests:

• •Chest X-rays
  Reveal abnormal shadows.
• •CT scans
  Provide detailed anatomical information.
• •PET scans
  Assess metabolic activity.
• •Octreotide scans
  Detect NET-specific features.

Bronchoscopy allows direct airway visualisation and biopsy of visible tumours.

• •Bronchoscopy
  allows direct airway visualisation and biopsy of visible tumours.
• •Biopsy
  confirms diagnosis through microscopic tissue examination. Immunohistochemistry identifies neuroendocrine features.
• •Blood and hormone tests
  measure chromogranin A levels and specific hormone assays based on symptoms.

Neuroendocrine Tumour Lung Treatment

The treatment varies dramatically based on tumour type and stage.

• •Surgery
  remains the primary treatment for localised low-grade and intermediate-grade NETs. Complete removal offers the best chance of cure. Procedures range from wedge resections to pneumonectomy. Lymph node removal accompanies tumour resection for staging.
• •Chemotherapy
  forms the backbone of high-grade NET treatment. Small cell lung cancer responds initially to platinum-based regimens like cisplatin plus etoposide. Lower-grade NETs show poor chemotherapy responsiveness, requiring alternative approaches.

Targeted therapy benefits certain NET patients:

• •Everolimus
  Inhibits mTOR signalling, slowing progression in advanced carcinoids.
• •Somatostatin analogues
  Control hormone symptoms effectively.
• •Peptide receptor radionuclide therapy
  Delivers targeted radiation to tumour sites.

Radiation therapy palliates symptoms from brain or bone metastases. Prophylactic cranial irradiation prevents brain metastases in small cell cancer.

Liver-directed therapies address hepatic metastases through radiofrequency ablation and chemoembolisation.

Moving Forward with Lung NET Diagnosis

Neuroendocrine tumour lung cure remains possible for early-stage low-grade disease. Surgical removal achieves long-term survival frequently.

Connecting with NET specialists significantly improves care quality. Research continues to advance treatment options. However, living with lung NETs requires ongoing monitoring.

Find NET specialists experienced in managing lung neuroendocrine tumours.